Status:
COMPLETED
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
Lead Sponsor:
SynerGene Therapeutics, Inc.
Conditions:
Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase I study designed to evaluate the safety and maximum tolerated dose (MTD) of SGT-94, a novel, tumor-targeted, systemic gene therapy agent for cancer. In addition, we will look for evide...
Detailed Description
RB94, a tumor suppressor gene, is a modified form of the retinoblastoma gene, RB110. RB94 has shown enhanced tumor suppressor and tumor cell killing activity compared to RB110 in all tumor cell types ...
Eligibility Criteria
Inclusion
- Histologic proof of cancer for which no standard therapy is available, and which shows no staining for RB by IHC.
- Spirometry with at least 70% of predicted volumes (including FEV1). A left ventricular ejection fraction (LVEF) of 45% or more. All patients will have a screening 2-D Echocardiogram as part of eligibility screening.
- Patients must have adequate physiologic reserve as evidenced by:
- Zubrod Performance Status (PS) of \</= 2; or 3 if of recent onset (i.e. \< 2 weeks) and if the compromised performance status is related to uncontrolled pain which is expected to come under control by means of improved pain management.
- Laboratory values meeting the following criteria:
- Absolute neutrophil count \>/= 1,200/mm3
- Platelet count \>100,000/mm3.
- AST and ALT \</= 3x the upper limit of normal
- Conjugated bilirubin \</= 1.5 mg/dL (or total bilirubin \</= 2.5 mg/dL)
- Native kidney function producing creatinine clearance (either measured or estimated by Cockcroft formula) of at least 40 mL/min. Cockcroft formula: CLcr = \[(140-age) • wt(kg)\]/\[72 •Creat (mg/dL)\] (For females, multiply by 0.85)
- Hemoglobin \>/= 10.0 g/dL without transfusion support
- White blood cell count \> 3.0 k/mm3
- PT and aPTT each \< 1.5 times the upper limit of normal.
- Women of child-bearing potential must have a negative pregnancy test.
- Male and female patients reproductive potential must agree to use measures to avoid pregnancy throughout the study and for 3 months following discontinuing study drug.
- Patients must have recovered from any previous therapy side effects or toxicities prior to initiating protocol study infusions.
- Life expectancy \> 12 weeks.
- Organ function \</= grade 1.
- Age of \</= 18 years.
Exclusion
- Some prior cancer therapies are not consistent with eligibility; specifically:
- At least 30 days must have elapsed since any prior experimental therapy
- At least 6 weeks must have elapsed since prior systemic mitomycin C
- At least 8 weeks must have elapsed since any dose of Strontium-89
- At least 4 weeks must have elapsed since prior Sm-153 lexidronam (Quadramet™)
- At least 4 weeks must have elapsed since prior radiotherapy
- Any prior exposure to gene vector delivery products
- Pregnancy or lactation
- Serious concurrent medical illness that in the opinion of the investigator would compromise patient safety or preclude accurate assessment of outcome.
- Patients with the following manifestations of cardiovascular disease are excluded:
- Myocardial infarction (MI) within the previous six months, or patients with left ventricular ejection fraction of less than 45% secondary to a more remote MI.
- Any history of CVA or TIA in previous six months
- New York Heart Association grade 2 or greater congestive failure
- Unstable angina defined as angina (or anginal equivalent) 2 or more times per week despite medical therapy.
- Echocardiographic evidence of pulmonary hypertension.
- Diastolic dysfunction felt to contribute to any clinical sign or symptom.
- Uncontrolled hypertension, defined as systolic BP \>140 or diastolic \>90 despite therapy.
- Serious concurrent psychiatric disorder that in the opinion of the investigator would compromise patient safety or preclude accurate assessment of outcome.
- Supraphysiologic doses of glucocorticoids (defined as \> 30 mg of hydrocortisone per day or \> 7.5 mg of Prednisone per day, or equivalent doses of other agents) or exposure to other immunosuppressive medications in the previous 30 days.
- Requirement for anticoagulant therapy other than low intensity treatment to maintain patency of central venous catheters.
- Treatment with antibiotics for proven infection within 1 week prior to study entry or signs and symptoms consistent with an active infection or fever \> 38.1 C.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01517464
Start Date
January 1 2012
End Date
December 1 2015
Last Update
April 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States, 77030